New MRI assessment algorithms should be used to distinguish fibroids from cancerous growths, allowing women to avoid unnecessary hysterectomy.
The lifetime risk of developing uterine cancer stands at 1 in 33, with endometrial cancer comprising over 90% of cases. Fortunately, advancements in medical technology have enabled the early detection of endometrial cancer through methods such as ultrasound and endometrial biopsy. Symptoms, including abnormal bleeding, serve as crucial indicators prompting further investigation. Moreover, risk factors like obesity and diabetes, along with estrogen exposure, provide avenues for targeted preventive measures and vigilant screening. There is no doubt a hysterectomy is needed to treat endometrial cancers.
However, the challenge lies in discerning between benign and malignant uterine wall tumors, particularly sarcomas, which account for less than 10% of uterine cancers. These sarcomas present a diagnostic dilemma, often masquerading as benign fibroids, which are considerably more common. While the lifetime risk of sarcoma is 5 in 100,000, fibroids are very common, affecting 70% of women. Remarkably, sarcoma is discovered in merely 2 out of 1,000 hysterectomies performed for fibroids. In other words, fibroids are very common but sarcomas are very rare. Balancing the rarity of sarcomas and hysterectomy risks, the American College of Obstetricians and Gynecologists does not recommend hysterectomy solely to rule out sarcoma.
Moreover, the landscape of diagnostic capabilities is evolving. Traditional methods like ultrasound struggle to reliably identify sarcomas, but emerging MRI assessment algorithms show promise in distinguishing between benign fibroids and malignant sarcomas reliably with very high accuracy.
It’s crucial to contextualize these statistics within the broader spectrum of cancer risks faced by women. While uterine sarcomas are indeed a concern, they pale in comparison to the prevalence of breast cancer 1/8, lung cancer1/17, colon cancer1/25, and ovarian cancer 1/80. With a lifetime risk of less than 1 /20,000, uterine sarcomas occupy a distinctly rare niche. Just as we don’t advocate for prophylactic breast removal to prevent breast cancer, it follows that the indiscriminate removal of the uterus as a preventive measure for uterine sarcomas lacks logical grounding, especially considering the availability of advanced diagnostic imaging.
In conclusion, development of MRI assessment algorithm underscores the need for a nuanced approach to evaluate sarcoma risk in women with fibroids. Hysterectomy for fibroids should not be performed soley to rule out uterine sarcoma.
References: